Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market Size To Hit US$ 4.02 Billion By 2030

The global enzyme-linked immunosorbent assay (ELISA) testing market size is expected to hit around USD 4.02 billion by 2030 and progressing a CAGR of 6.4% over the forecast period 2022 to 2030.

 

The on enzyme-linked immunosorbent assay (ELISA) testing Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1260

Scope of the Report

Report Highlights	Details
Market Size	USD 4.02 Billion by 2030
Growth Rate	CAGR of 6.4% From 2021 to 2030
Base Year	2020
Forecast Period	2021 to 2030
Segments Covered	Test, Application, Region
Companies Mentioned	Thermo Fisher Scientific, Inc., ALPCO, Bio-Rad Laboratories, Inc., BD, BioMérieux SA, Ortho Clinical Diagnostics, R&D Systems, Inc., ZEUS Scientific, Inc.

A recent report provides crucial insights along with application based and forecast information in the Global Enzyme-linked immunosorbent assay (ELISA) testing Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Enzyme-linked immunosorbent assay (ELISA) testing market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Enzyme-linked immunosorbent assay (ELISA) testing market are included as given below:

Enzyme-linked immunosorbent assay (ELISA) testing Market Key Players

• Thermo Fisher Scientific, Inc.
• American Laboratory Products Company (ALPCO)
• Bio-Rad Laboratories, Inc.
• BD
• BioMérieux SA
• Ortho Clinical Diagnostics
• R&D Systems, Inc.
• ZEUS Scientific, Inc.

Market Segments

 By Test Type

• Sandwich ELISA
• Indirect ELISA
• Multiple and Portable ELISA
• Competitive ELISA
• Others

By Application

• Immunology
• Inflammation
• Infectious diseases
• Cancer
• Protein quantification
• Other Applications

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Report Objectives

• To define, describe, and forecast the global enzyme-linked immunosorbent assay (ELISA) testing market based on product, and region
• To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
• To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
• To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the enzyme-linked immunosorbent assay (ELISA) testing market

Table of Content

 Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Test Type

7.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Test Type, 2021-2030

7.1.1. Sandwich ELISA

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Indirect ELISA

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Multiple and Portable ELISA

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Competitive ELISA

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. Others

7.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, By Application

8.1. Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, by Application, 2021-2030

8.1.1. Immunology

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Inflammation

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Infectious diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Cancer

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Protein quantification

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Other Applications

8.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Enzyme-Linked Immunosorbent Assay (ELISA) Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.2. Market Revenue and Forecast, by Application (2017-2030)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.4.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.2. Market Revenue and Forecast, by Application (2017-2030)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.3.2. Market Revenue and Forecast, by Application (2017-2030)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.4.2. Market Revenue and Forecast, by Application (2017-2030)

Chapter 10. Company Profiles

10.1. Thermo Fisher Scientific, Inc.

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. American Laboratory Products Company (ALPCO)

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Bio-Rad Laboratories, Inc.

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. BD

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. BioMérieux SA

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Ortho Clinical Diagnostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. R&D Systems, Inc.

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. ZEUS Scientific, Inc.

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com